Parathyroid hormone

DB05829

biotech approved investigational

Deskripsi

Parathyroid hormone (PTH) is a single-chain polypeptide composed of 84 amino acids. Available as Preotact, it is an identical form of human recombinant hormome which produced as a fusion protein undergoeing post-translational processing involving the cleavage of the OmpA leader sequence, leaving the mature protein as a single-chain 84 amino-acids polypeptide (9.4 kDa).

Preotact is used in the treatment of osteoporosis in postmenopausal women at high risk of osteoporotic fractures and is marketed in Europe by Nycomed. Preos is a registered trade mark owned by NPS Pharmaceuticals, Inc. The name Preos and the New Drug Application is pending approval by the U.S. Food and Drug Administration (FDA).

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) 1.5 hours.
Volume Distribusi The volume of distribution at steady-state following intravenous administration is approximately 5.4 liters with an interpatient variability of about 40%.
Klirens (Clearance) -

Absorpsi

The absolute bioavailability after subcutaneous administration in the abdomen is 55% for doses of 100 micrograms.

Metabolisme

PTH is primarily metabolised in the liver with lesser contributions by the kidney. Amino terminal fragments are metabolised in the liver while carboxyl terminal groups travel to the kidney for metabolism where they are also thought to have a role in regulation of PTH. Only about 30% of circulating hormone is present as the unfragmented form.

Rute Eliminasi

Carboxy-terminal fragments are filtered by the kidney and subsequently broken down into even smaller fragments during tubular reuptake.

Interaksi Obat

213 Data
Digoxin The risk or severity of adverse effects can be increased when Parathyroid hormone is combined with Digoxin.
Acetyldigitoxin The risk or severity of adverse effects can be increased when Parathyroid hormone is combined with Acetyldigitoxin.
Deslanoside The risk or severity of adverse effects can be increased when Parathyroid hormone is combined with Deslanoside.
Ouabain The risk or severity of adverse effects can be increased when Parathyroid hormone is combined with Ouabain.
Digitoxin The risk or severity of adverse effects can be increased when Parathyroid hormone is combined with Digitoxin.
Oleandrin The risk or severity of adverse effects can be increased when Parathyroid hormone is combined with Oleandrin.
Cymarin The risk or severity of adverse effects can be increased when Parathyroid hormone is combined with Cymarin.
Proscillaridin The risk or severity of adverse effects can be increased when Parathyroid hormone is combined with Proscillaridin.
Metildigoxin The risk or severity of adverse effects can be increased when Parathyroid hormone is combined with Metildigoxin.
Lanatoside C The risk or severity of adverse effects can be increased when Parathyroid hormone is combined with Lanatoside C.
Gitoformate The risk or severity of adverse effects can be increased when Parathyroid hormone is combined with Gitoformate.
Acetyldigoxin The risk or severity of adverse effects can be increased when Parathyroid hormone is combined with Acetyldigoxin.
Peruvoside The risk or severity of adverse effects can be increased when Parathyroid hormone is combined with Peruvoside.
Fluvoxamine The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Fluvoxamine.
Citalopram The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Citalopram.
Fluoxetine The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Fluoxetine.
Duloxetine The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Duloxetine.
Trazodone The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Trazodone.
Paroxetine The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Paroxetine.
Sertraline The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Sertraline.
Sibutramine The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Sibutramine.
Nefazodone The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Nefazodone.
Escitalopram The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Escitalopram.
Zimelidine The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Zimelidine.
Dapoxetine The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Dapoxetine.
Milnacipran The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Milnacipran.
Desvenlafaxine The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Desvenlafaxine.
Seproxetine The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Seproxetine.
Indalpine The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Indalpine.
Ritanserin The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Ritanserin.
Alaproclate The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Alaproclate.
Pamidronic acid The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Pamidronic acid.
Zoledronic acid The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Zoledronic acid.
Alendronic acid The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Alendronic acid.
Ibandronate The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Ibandronate.
Clodronic acid The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Clodronic acid.
Risedronic acid The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Risedronic acid.
Etidronic acid The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Etidronic acid.
Tiludronic acid The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Tiludronic acid.
Incadronic acid The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Incadronic acid.
Amphetamine The risk or severity of adverse effects can be increased when Amphetamine is combined with Parathyroid hormone.
Phentermine The risk or severity of adverse effects can be increased when Phentermine is combined with Parathyroid hormone.
Midodrine The risk or severity of adverse effects can be increased when Midodrine is combined with Parathyroid hormone.
Norepinephrine The risk or severity of adverse effects can be increased when Norepinephrine is combined with Parathyroid hormone.
Phenylephrine The risk or severity of adverse effects can be increased when Phenylephrine is combined with Parathyroid hormone.
Phenylpropanolamine The risk or severity of adverse effects can be increased when Phenylpropanolamine is combined with Parathyroid hormone.
Metaraminol The risk or severity of adverse effects can be increased when Metaraminol is combined with Parathyroid hormone.
Epinephrine The risk or severity of adverse effects can be increased when Epinephrine is combined with Parathyroid hormone.
Methoxamine The risk or severity of adverse effects can be increased when Methoxamine is combined with Parathyroid hormone.
Orciprenaline The risk or severity of adverse effects can be increased when Orciprenaline is combined with Parathyroid hormone.
Phenmetrazine The risk or severity of adverse effects can be increased when Phenmetrazine is combined with Parathyroid hormone.
Dobutamine The risk or severity of adverse effects can be increased when Dobutamine is combined with Parathyroid hormone.
Pseudoephedrine The risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Parathyroid hormone.
Benzphetamine The risk or severity of adverse effects can be increased when Benzphetamine is combined with Parathyroid hormone.
Ritodrine The risk or severity of adverse effects can be increased when Ritodrine is combined with Parathyroid hormone.
Terbutaline The risk or severity of adverse effects can be increased when Terbutaline is combined with Parathyroid hormone.
Oxymetazoline The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Parathyroid hormone.
Diethylpropion The risk or severity of adverse effects can be increased when Diethylpropion is combined with Parathyroid hormone.
Dopamine The risk or severity of adverse effects can be increased when Dopamine is combined with Parathyroid hormone.
Isoprenaline The risk or severity of adverse effects can be increased when Isoprenaline is combined with Parathyroid hormone.
Lisdexamfetamine The risk or severity of adverse effects can be increased when Lisdexamfetamine is combined with Parathyroid hormone.
Fenoterol The risk or severity of adverse effects can be increased when Fenoterol is combined with Parathyroid hormone.
Ephedrine The risk or severity of adverse effects can be increased when Ephedrine is combined with Parathyroid hormone.
Mephentermine The risk or severity of adverse effects can be increased when Mephentermine is combined with Parathyroid hormone.
Procaterol The risk or severity of adverse effects can be increased when Procaterol is combined with Parathyroid hormone.
Clenbuterol The risk or severity of adverse effects can be increased when Clenbuterol is combined with Parathyroid hormone.
MMDA The risk or severity of adverse effects can be increased when MMDA is combined with Parathyroid hormone.
Midomafetamine The risk or severity of adverse effects can be increased when Midomafetamine is combined with Parathyroid hormone.
2,5-Dimethoxy-4-ethylamphetamine The risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylamphetamine is combined with Parathyroid hormone.
4-Bromo-2,5-dimethoxyamphetamine The risk or severity of adverse effects can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with Parathyroid hormone.
Tenamfetamine The risk or severity of adverse effects can be increased when Tenamfetamine is combined with Parathyroid hormone.
Chlorphentermine The risk or severity of adverse effects can be increased when Chlorphentermine is combined with Parathyroid hormone.
Methylenedioxyethamphetamine The risk or severity of adverse effects can be increased when Methylenedioxyethamphetamine is combined with Parathyroid hormone.
Dextroamphetamine The risk or severity of adverse effects can be increased when Dextroamphetamine is combined with Parathyroid hormone.
Metamfetamine The risk or severity of adverse effects can be increased when Metamfetamine is combined with Parathyroid hormone.
Nylidrin The risk or severity of adverse effects can be increased when Nylidrin is combined with Parathyroid hormone.
Tetryzoline The risk or severity of adverse effects can be increased when Tetryzoline is combined with Parathyroid hormone.
Tyramine The risk or severity of adverse effects can be increased when Tyramine is combined with Parathyroid hormone.
Isoxsuprine The risk or severity of adverse effects can be increased when Isoxsuprine is combined with Parathyroid hormone.
Etilefrine The risk or severity of adverse effects can be increased when Etilefrine is combined with Parathyroid hormone.
Synephrine The risk or severity of adverse effects can be increased when Synephrine is combined with Parathyroid hormone.
Iofetamine I-123 The risk or severity of adverse effects can be increased when Iofetamine I-123 is combined with Parathyroid hormone.
Racepinephrine The risk or severity of adverse effects can be increased when Racepinephrine is combined with Parathyroid hormone.
Ritobegron The risk or severity of adverse effects can be increased when Ritobegron is combined with Parathyroid hormone.
Tramazoline The risk or severity of adverse effects can be increased when Tramazoline is combined with Parathyroid hormone.
Mephedrone The risk or severity of adverse effects can be increased when Mephedrone is combined with Parathyroid hormone.
Fenozolone The risk or severity of adverse effects can be increased when Fenozolone is combined with Parathyroid hormone.
Methoxyphenamine The risk or severity of adverse effects can be increased when Methoxyphenamine is combined with Parathyroid hormone.
Tretoquinol The risk or severity of adverse effects can be increased when Tretoquinol is combined with Parathyroid hormone.
Gepefrine The risk or severity of adverse effects can be increased when Gepefrine is combined with Parathyroid hormone.
Prenalterol The risk or severity of adverse effects can be increased when Prenalterol is combined with Parathyroid hormone.
Mefenorex The risk or severity of adverse effects can be increased when Mefenorex is combined with Parathyroid hormone.
2,5-Dimethoxy-4-ethylthioamphetamine The risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylthioamphetamine is combined with Parathyroid hormone.
Labetalol The risk or severity of adverse effects can be increased when Labetalol is combined with Parathyroid hormone.
Acebutolol The risk or severity of adverse effects can be increased when Acebutolol is combined with Parathyroid hormone.
Celiprolol The risk or severity of adverse effects can be increased when Celiprolol is combined with Parathyroid hormone.
Bucindolol The risk or severity of adverse effects can be increased when Bucindolol is combined with Parathyroid hormone.
Epanolol The risk or severity of adverse effects can be increased when Epanolol is combined with Parathyroid hormone.
Gefitinib The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Gefitinib.
Sorafenib The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Sorafenib.

Target Protein

Parathyroid hormone 2 receptor PTH2R
Parathyroid hormone/parathyroid hormone-related peptide receptor PTH1R

Referensi & Sumber

Synthesis reference: Robert L. Colescott, Geoffrey W. Tregear, "Synthesis of peptides with parathyroid hormone activity." U.S. Patent US4105602, issued May, 1977.
Artikel (PubMed)

Contoh Produk & Brand

Produk: 9 • International brands: 1
Produk
  • Natpar
    Injection, powder, for solution • 25 ?g • Subcutaneous • EU • Approved
  • Natpar
    Injection, powder, for solution • 50 ?g • Subcutaneous • EU • Approved
  • Natpar
    Injection, powder, for solution • 75 ?g • Subcutaneous • EU • Approved
  • Natpar
    Injection, powder, for solution • 100 ?g • Subcutaneous • EU • Approved
  • NATPARA (parathyroid hormone)
    Injection, powder, lyophilized, for solution • 25 ug/0.08mL • Subcutaneous • US • Approved
  • NATPARA (parathyroid hormone)
    Injection, powder, lyophilized, for solution • 50 ug/0.08mL • Subcutaneous • US • Approved
  • NATPARA (parathyroid hormone)
    Injection, powder, lyophilized, for solution • 75 ug/0.08mL • Subcutaneous • US • Approved
  • NATPARA (parathyroid hormone)
    Injection, powder, lyophilized, for solution • 100 ug/0.08mL • Subcutaneous • US • Approved
Menampilkan 8 dari 9 produk.
International Brands
  • Preos — NPS Pharmaceuticals, Inc.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul